HQL-79
HQL-79, a potent, selective and orally active human hematopoietic prostaglandin D synthase (H-PGDS) inhibitor, highly selectively inhibits the synthesis of PGD2, and acts as an anti-allergic agent, with a Kd of 0.8 μM and an IC50 of 6 μM. Shows no obvious effect on COX-1, COX-2, m-PGES, or L-PGDS[1].
Product Specifications
CAS Number
162641-16-9
UNSPSC
12352005
Target
PGE synthase
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/hql-79.html
Purity
99.89
Solubility
DMSO : 2 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
N1(CCCC2=NN=NN2)CCC(OC(C3=CC=CC=C3)C4=CC=CC=C4)CC1
Molecular Formula
C22H27N5O
Molecular Weight
377.48
References & Citations
[1]Aritake K, et al. Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J Biol Chem. 2006 Jun 2;281 (22) :15277-86. Epub 2006 Mar 17.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
32980064 1.0 µg DNA
Olfr20 Lentiviral Vector (Mouse) (CMV) (pLenti-GIII-CMV)
Sign In for Pricing
View Details HP220609 200 Reactions
LOC389705 Human qPCR Primer Pair (NR_003920)
Sign In for Pricing
View Details 